A Study of Zidovudine in HIV-Infected Patients Who Have Hemophilia
Public ClinicalTrials.gov record NCT00001104. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Placebo Controlled Trial To Evaluate Zidovudine (ZDV) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Hemophilic Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Study A: To determine whether treatment with zidovudine (ZDV) will delay or change the disease process in hemophilic patients who have HIV infection with no symptoms. The major clinical question is whether patients who receive chronic ZDV therapy will have a delay in the development of AIDS or AIDS-related complex (ARC). The pharmacokinetics (blood levels) of ZDV in hemophilic patients will also be studied. Study B: To determine if ZDV therapy changes the risk of a hemophiliac transmitting HIV to his wife or other female sexual partner. To determine the effectiveness of counseling and education on the behaviors of the wives that place them at risk for HIV infection. To determine if antibodies to HIV either appear or disappear from the blood of any of the wives during the study. Study A: Individuals who are infected with HIV can benefit from therapy with an effective anti-AIDS virus agent. ZDV is a potent inhibitor of HIV in vitro (test tube) and is safe in humans at the dose planned. It may be effective in preventing the development of AIDS or ARC in hemophiliacs who have the HIV antibody in their blood. The pharmacokinetic studies are especially important because the high prevalence of hepatic disease in this population may affect the metabolism and blood levels of ZDV. Study B: HIV is transmitted by sexual contact, and wives of infected hemophilic patients have become infected during long-term sexual relationships. Transmission of the virus does not occur during casual family contact. This study will aid in determining if therapy influences the transmission of HIV, because the wives of hemophiliacs generally have no risk for HIV infection other than sexual contact with their spouse.
Study identification
- NCT ID
- NCT00001104
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 538 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Jan 31, 1990
- Last update posted
- Oct 31, 2021
Ends 1990
United States locations
- U.S. sites
- 23
- U.S. states
- 12
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Los Angeles County - USC Med Ctr | Los Angeles | California | 90033 | — |
| Univ of California / San Diego Treatment Ctr | San Diego | California | 921036325 | — |
| Stanford Univ School of Medicine | Stanford | California | 94305 | — |
| Northwestern Univ Med School | Chicago | Illinois | 60611 | — |
| Cook County Hosp | Chicago | Illinois | 60612 | — |
| Chicago Children's Memorial Hosp | Chicago | Illinois | 606143394 | — |
| Indiana Univ Hosp | Indianapolis | Indiana | 462025250 | — |
| Tulane Univ School of Medicine | New Orleans | Louisiana | 70112 | — |
| Children's Hosp of Boston | Boston | Massachusetts | 021155724 | — |
| Univ of Massachusetts Med Ctr | Worcester | Massachusetts | 01655 | — |
| Univ of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Cornell Univ Med Ctr | New York | New York | 10021 | — |
| Mount Sinai Med Ctr | New York | New York | 10029 | — |
| Univ of Rochester Medical Center | Rochester | New York | 14642 | — |
| Univ of North Carolina | Chapel Hill | North Carolina | 275997215 | — |
| Holmes Hosp / Univ of Cincinnati Med Ctr | Cincinnati | Ohio | 452670405 | — |
| Univ Hosp of Cleveland / Case Western Reserve Univ | Cleveland | Ohio | 44106 | — |
| Ohio State Univ Hosp Clinic | Columbus | Ohio | 432101228 | — |
| Milton S Hershey Med Ctr | Hershey | Pennsylvania | 170330850 | — |
| Hemophilia Ctr of Western PA / Univ of Pittsburgh | Pittsburgh | Pennsylvania | 15219 | — |
| Univ of Pittsburgh Med School | Pittsburgh | Pennsylvania | — | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| Univ of Washington | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00001104, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 31, 2021 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00001104 live on ClinicalTrials.gov.